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Abstract
The technique of small-molecule microarray (SMM) screening is based on the ability of small 
molecules to bind to various soluble proteins. This type of interaction is easily detected by the 
presence of a fluorescence signal produced by labeled antibodies that specifically recognize a 
unique sequence (tag) present on the target protein. The fluorescent signal intensity values are 
determined based on signal-to-noise ratios (SNR). SMM screening is a high throughput, unbiased 
method that can rapidly identify novel direct ligands for various protein targets. This binding-
based assay format is generally applicable to most proteins, but it is especially useful for protein 
targets that do not possess an enzymatic activity. SMMs enable screening a protein in a purified 
form or in the context of a cellular lysate, likely providing a more physiologically relevant 
screening environment.
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Introduction
This article describes the general procedure for small-molecule microarray (SMM) 
screening whereby the primary goal is to identify putative binders to a given protein target 
or protein complex. Several probe discoveries enabled by SMMs have been recently 
reviewed (Hong et al., 2014). The process for manufacturing microarrays also has been 
reviewed previously (Shi et al., 2010; Uttamchandani et al., 2004; Uttamchandani and Yao, 
2010; Vegas and Koehler, 2010; Walsh and Chang, 2004) and is not the focus of this 
protocol. The reader is referred to previous step-by-step protocols focused on the 
manufacture of SMMs (Bradner et al., 2006; Casalena et al., 2012). The SMM assay is 
based on the ability of compounds corresponding to various types of chemical structures to 
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directly bind to soluble proteins, with specificity that depends on the properties of the small 
molecule as well as the three-dimensional structure of the protein surface. Highly specific 
antibodies that recognize a unique tag sequence engineered at either terminus of the target 
protein identify putative interactions between compounds and targets. The detection is based 
on a fluorescent signal generated by dyes (e.g., Cy3, Cy5) linked to the primary antibody. 
Alternatively, a labeled secondary antibody can be used to bind unlabeled primary 
antibodies. The fluorescent signal is recorded with a microarray scanner that generates an 
image file and the signal intensities can be analyzed using various methods but the most 
common analysis methods focus on signal-to-noise ratios.
The protocol presented herein describes a screening approach involving a tagged-target 
protein in the context of a cell lysate, and has been successfully applied previously to 
recalcitrant targets such as transcriptional regulators and extracellular factors (Miyazaki et 
al., 2010; Pop et al., 2014; Stanton et al., 2009). Lysate-based binding assays enable 
researchers to uncover different types of probes from screens using purified proteins. In 
lysates, target proteins can be closer to their native folded states and often have post-
translational modifications that might be important for their activity. The lysate format can 
provide the right environment for target proteins to remain engaged with other protein or 
nucleic acid binding partners, which in turn enhances their stability. Additionally, screening 
using lysates enables researchers to identify multiple types of assay positives. Some 
compounds may bind the target of interest directly, while others may bind to a binding-
partner protein, which may have an impact on the function of the target of interest. 
Obtaining a pool of assay positives that might interact with various domains of a target 
protein or to binding partners is very powerful when dealing with novel targets, particularly 
those that function in biomolecular complexes. Screening using lysates may also enable 
methods to identify novel modes of modulating conventional targets. A key technical 
advantage of lysate screens over purified protein screens relates to soluble proteins present 
in the lysate that serve as blocking agents, dramatically reducing background signals and 
leading to data of overall higher quality. While the protocol described herein is focused on 
recombinantly tagged and expressed protein, the lysate approach can also involve detection 
of small molecules that bind to endogenous proteins, when expression levels are sufficient 
and direct antibodies are available.
Strategic planning
This protocol is compatible with SMMs manufactured using multiple surface capture 
strategies or formats and assumes that printed SMMs are available at the time of the 
screening. The screener should consider whether the surface chemistry used for SMM 
manufacture results in a linkage that is stable to cellular esterases prior to executing the 
screen. Please refer to the previously published protocols on SMM manufacture for lysate-
compatible arrays (Casalena et al., 2012) or reviews that thoroughly discuss the multitude of 
options for array manufacture, including surface capture strategies and array layouts 
(Uttamchandani et al., 2010). Typical SMMs vary in the amount of printed features with a 
range of 1,000–16,000 printed features. Nearly all SMM formats contain both positive and 
negative controls. Fluorescent dyes may be used as positive controls for SMM manufacture, 
monitoring the fidelity of surface chemistry and washing steps, and they may serve as 
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printed sentinels that help to frame the array. These dye sentinels are often helpful when 
analyzing the SMM image data as they anchor the image analysis and array content files. 
The dyes are often chosen to be orthogonal from the dye used for detecting protein-small 
molecule interactions. For example, we often array an amine-tagged version of fluorescein 
or Alexa Fluor 488 for the sentinel controls and we use tagged antibodies or proteins for 
detection that are fluorescent in the red region (~650/670 nm). Other typical positive 
controls include small molecules with known protein partners that are commercially 
available such as biotin (streptavidin) and rapamycin or FK506 (FKBP12). The positive 
controls can be useful in monitoring the quality of SMM manufacture and are typically 
included in each of the printed subarrays that correspond to a given pin. If known ligands are 
available for the target of interest, these compounds may also be printed on the arrays if the 
compound is compatible with the chosen surface-capture strategy. For many recalcitrant 
targets, there are no known positive controls for the screen as there are no known ligands. 
Depending on the nature of the surface and the chemical composition of the printed 
compounds, SMMs can typically be stored for 6–12 months at −20 °C and with protection 
from light. This article focuses on the SMM screening procedure using HEK293 cell lysate 
expressing the target of choice tagged with HA tag (or any other appropriate tag, including 
encoded fluorescent tags such as GFP or mCherry). The preparation of the screening lysate 
is detailed in the Support Protocol.
Alternate strategy for target expression
Endogenous targets
In some instances a target can be sufficiently expressed endogenously to allow detection on 
the array. If highly specific antibodies are available for such proteins it is preferable to 
screen in such conditions, therefore eliminating any non-physiologic interactions resulting 
from overexpression. Key considerations for this assay format include the quality of the 
antibody reagents and the possibility that direct antibody interactions with the protein may 
affect the interaction of a small molecule with the protein target (Bradner).
Exogenous targets
For some targets, expression in HEK293T cells may not be the optimal cellular context and 
therefore it may be more physiologically relevant to use a cell line that is more pertinent to 
the target in question. Ideally the selected cell line grows well in cell culture conditions and 
is efficiently transfectable. If transient transfection is not suitable, a lentiviral infection can 
be used.
Support Protocols
Support protocol A: Expression and target quantification
Certain target proteins are not amenable to purification procedures. Such proteins tend to be 
either unstable or nonfunctional when extracted from their physiological environments. To 
overcome this potential difficulty we have optimized a screening assay that uses cell lysates 
expressing the target of choice where physiological conditions (post-translational 
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modifications, biological functions and folding are maintained). In this protocol, the target 
of interest is expressed in HEK293 cell line.
Materials
• HEK293T cell line (ATCC, cat# CRL-11268)
• The protein target cloned in a mammalian expression vector (i.e. pcDNA3.1) 
driven by CMV promoter and harboring the HA tag at either N- or C- termini
• Fugene6 transfection reagent (Promega cat# E2691)
• OptiMEM media (Life Technologies, cat# 11058-021) for transfection procedure
• DMEM cell culture media supplemented with 10% FBS and 1x penicillin/
streptomycin
• Cell culture plates (10 cm diameter)
• Cell culture sterile cabinets and mammalian cell culture incubators
Protocol
1 One day prior to transfection, seed 2 million HEK293 cells/10 cm plates. One 
plate can provide sufficient lysate to screen 3 SMM slides. Prepare several 
plates to generate mock lysates for use in assay development experiments aimed 
at optimizing the target concentration.
2 Prepare transfection mixture according to the transfection reagent protocol: mix 
5 μg plasmid DNA and OptiMEM media with Fugene6 (or transfection reagent 
of choice) in a 1:5 ratio (according to manufacturer protocol) and incubate for 
20 minutes at room temperature.
3 Transfer the transfection mix onto cells containing fresh media and incubate for 
48 hours
Support protocol B: Cell lysis and protein quantification
The SMM screening assay uses lysate generated from cells expressing the tagged target. 
Cell lysis buffer and its components permit extraction of the total cellular soluble protein 
and preserves the proteins including the target in a protected stable solution.
Materials
• MIPP lysis buffer (ice cold) supplemented with protease inhibitors
• PBS buffer (ice-cold)
• BSA (bovine Serum Albumin) solution 10 mg/mL
• Cell scrapers
• Eppendorf 5810 centrifuge
• BCA protein quantification reagents (Thermo Scientific, cat # 23225)
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• 96 well plate (non-sterile)
• Spectrophotometer
Protocol
4 Wash the plates containing the transfected cells with ice-cold PBS and remove 
the extra PBS buffer by maintaining the plates at an angle for one minute
5 Add 150 μl lysis buffer per plate and incubate on ice for 20 minutes
6 Collect the lysates from plates using the cell scrapers, transfer to a 1.5 mL tube 
and centrifuge at 13000 rpm/4°C for 10 minutes. Transfer and save the 
supernatant. This is the stock cell lysate.
7 Prepare BCA reagent mixture by mixing 20 μl reagent B in 1 mL reagent A and 
pipet 100 μl of this solution in the 96 well plate. Prepare triplicates for each 
concentration to be measured.
8 Generate a serial dilution for BSA concentrations (i.e. 10, 7.5, 5 and 2.5 mg/
mL). Pipet 1 μl of each dilution and lysate in the triplicate 96 wells mixing 
gently and incubate 30 min in the dark (i.e. drawer) at room temperature.
9 Using the spectrophotometer and determine the absorption values and based on 
the standard curve calculate the total protein concentration of stock lysate.
Support protocol C: Protein target quantification
In the SMM screen the target must be at a minimal concentration and a good starting point 
in this optimization is 0.5 μg/ml of diluted lysate (approximately at 0.3 mg/mL). This is 
easily achievable since in a typical overexpression experiment the target is expressed at 
about 0.5% of the total cellular protein.
Materials
• HA-tagged purified protein (any protein similar in size with the desired target) to 
be used as a quantification reference
• Western blot materials and instruments (SDS protein gel, protein markers, buffers, 
transfer membrane, gel running chamber, power supply, gel transfer apparatus, etc)
• Anti HA antibody (Covance, cat# MMS-101P)
• Appropriate secondary labeled-antibody (i.e. for Odyssey detection or HRP based)
• Densitometry software (ImageQuant, ImageJ, Odyssey)
Protocol
10 Prepare SDS PAGE samples containing target-expressing stock lysate at 25, 50 
and 75 μg protein/sample. Prepare samples containing 0.1, 0.2, 0.4 and 0.8 μg 
purified HA-tagged protein. The remaining lysate is the stock lysate and can be 
flash frozen in liquid nitrogen for short-term storage at −80°C.
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11 Perform a western blot analysis for these samples using an anti-HA antibody 
coupled to a secondary readout (e.g. chemiluminescence or fluorescence) to 
visualize protein.
12 Use standard densitometry software (such as the software that often comes with 
an imager used to detect signal on blots) to quantify the signal in each lane. 
Based on the signal values for the purified reference, calculate how much target 
protein is present per mL of stock lysate. Use this information for assay 
development procedure in step 21 of basic protocol.
Basic Protocol: SMM Screening
Materials
• Printed small-molecule microarray (SMM) slides, four replicate arrays (Casalena et 
al., 2012, Uttamchandani et al., 2010).
• HEK293T lysate containing HA-tagged target protein and mock lysate prepared as 
described in the support protocol
• MIPP lysis buffer (see recipe)
• Rocking shaker
• 4-well dishes for slide incubation from (VWR, 7321-424).
• HA antibody, fluorophore-labeled (e.g. Cy5 or Cy3) (Cell Signaling, cat# 3444) 
secondary antibody. High-quality conjugated antibodies are available from a 
number of vendors. For example, a Cy5-labeled anti-HA antibody is available from 
Bioss Inc. (cat # bs-0966R-Cy5).
• TBS-T buffer (see recipe)
• Milli-Q water or equivalent
• Laboratory Slide Spinner (Labnet, C1303T)
• Microarray scanner GenePix 4200A (Molecular Devices)
• GenePix Pro software (Molecular Devices)
• FKBP12 control protein, this protein is available in various tagged formats (e.g. 
His-tag, GST-tag, etc.) from multiple vendors. One can consider using various tags 
as a control depending upon the detection strategy for your target of interest. The 
carrier-free and His-tagged sample from R&D Systems (cat # 3777-FK100) is 
recommended.
• Rapamycin, ligand of FKBP12 (LC Labs, R-5000)
• Alexa647-labeled Streptavidin control protein (Life Technologies, cat # S21374)
• biotin-cadaverine as ligand of streptavidin (Life Technologies, cat # A-1594)
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In order to perform an optimal SMM lysate-based screen, a few assay development 
experiments need to be designed and executed. Due to the varying nature of expression 
levels between cell lines and various target proteins, it is imperative that the assay 
development round is completed in the lysate of the expression systems chosen for the 
target. The goal of assay development is to optimize the ratio of protein target and total 
protein lysate concentrations in order to minimize background noise and maximize positive 
signals when the assay is read out.
A. Assay development procedure—SMM slides are stored at −20C until executing the 
screening procedure. Before starting the SMM screen/assay development, acclimatize the 
slides to room temperature. Each assay development round should contain at least two 
identical slides per condition with duplicate compounds present on each slide, and should 
contain a positive control. For example, Rapamycin, a small molecule that binds to FKBP12, 
and biotin, a small molecule that binds to streptavidin, may be printed throughout the array 
as controls. Stock concentrations and storage conditions for proteins can vary according to 
the nature of the protein. Protein stocks can be stored in nearly any buffer but caution should 
be taken to avoid autofluorescent buffer components such as some detergents. When in 
doubt about the autofluorescent potential of a given buffer composition, we typically suggest 
incubating a blank microscope slide in the desired buffer, drying and scanning at the desired 
detection wavelengths to determine if the buffer leaves a fluorescent film that will interfere 
with the assay.
1 Prepare four solutions of purified FKBP12 protein diluted in TBST (6 mL) with 
the following protein concentrations: 0.1 μg/mL, 0.25 μg/mL, 0.5 μg/mL, and 1 
μg/mL
2 Prepare another set of five FKBP12 protein solutions, only this time instead of 
diluting in TBST, dilute the protein in cell lysate that has been diluted in MIPP 
buffer (6 mL) as follows:
• Add 0.25 μg/mL FKBP12 to 6 mL of diluted lysate containing 0.3 mg/mL 
total lysate protein. This concentration should yield very low assay signal.
• Add 0.5 μg/mL FKBP12 into diluted lysate containing 0.3 and 1 mg/mL 
total lysate protein (6 mL each).
• Add 1 μg/mL of FKBP12 into diluted lysate containing 0.3 and 1 mg/mL 
total lysate protein (6 mL each), respectively.
Note: total protein concentrations in stock lysate vary between 7 and 30 
mg/mL or greater and it should be quantified ahead of time using suitable 
method of choice such as BCA protein quantification.
3 Place slides in 4-well slide dishes (4 slides/dish; 5 dishes required).
4 Add 3 mL of each protein solution or diluted lysate solution to each slide. There 
should be a total of 18 slides, 8 conditions from step 1 and 10 conditions from 
step 2.
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5 Incubate the dishes with slides at 4°C, rocking gently for two hours.
6 Remove covers of 4-well dishes, set aside and fill the covers with TBST (~5 mL 
each).
7 Remove the slides from 4-well dishes and place them in TBST-filled covers (4 
slides/cover). Make sure there is enough TBST in the covers so slides are fully 
submerged. Place on gentle rocking for 5 min.
8 Discard TBST, keeping slides in covers, and add more TBST (~5 mL). Wash 
slides a total of 3 times with 5 mL TBST each time.
9 While slides are washing, prepare a 1:1000 dilution of labeled anti-HA antibody 
into TBST buffer. Prepare a sufficient volume for the number of slides tested on 
that day assuming 3 mL volume per slide.
10 Pipette the antibody solution into fresh 4-well dishes (3 mL per well). Remove 
slides from TBST and place them into antibody filled wells.
11 Place dishes on a gentle rocker at room temperature for 30 minutes.
12 Repeat steps 7 and 8 using Milli-Q water instead of TBST
Note: If anti-HA antibody is not labeled, use a secondary labeled antibody and 
repeat steps 7 trough 12
13 Remove slides and place them in slide centrifugal spinners for 30 seconds.
14 Place slides in Genepix scanner and scan at 635 wavelength, 600 PMT gain
B. Assay development data analysis
15 Save scanned image slides as Tiff files.
16 Using a .gal file generated by the arrayer, align regions of interests (ROIs) over 
the printed spots using the preferred software. Genepix 7.0 is the preferred 
software package that enables data analysis joining assignment of array content 
to scanner output. Note: a .gal file, otherwise known as gene-array list file from 
nucleic acid-based microarrays, is a file generated by the arrayer with the 
coordinates of each spot printed.
17 After the ROIs are assigned, run image analysis and save the results file, often 
called a “.gpr” file. Each saved analysis generates a .txt file containing 
compound identifiers (IDs) and corresponding fluorescent signals. The .txt file is 
compatible with analysis in various software environments such as Genepix, 
SpotFire, and Excel, among others.
18 Each spot will have an F635 value for the total fluorescence of that spot. There 
are 4 columns in the .gpr data file that will be used for signal analysis: block 
column, row column, F635 median and B635 median. The ‘block’ column and 
‘row’ columns contain information about the spot location, the F635 median 
column contains the total fluorescence on the particular spot and the B635 
median column contains fluorescence of the surrounding area around the spot.
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19 Using Excel or an alternative program, generate F/B ratios by dividing F635 
value by B635 value, which will result in a fold difference between a spot and 
its background. This is the number that will be used as signal for a given spot.
20 The assay development phase focuses on Rapamycin spots, which should 
generate signal in most of the 18 tested conditions.
As illustrated in Figure 1, Rapamycin signal will vary with FKBP12 
concentrations and is affected also by the protein concentration in the lysate. In 
this example it was determined that 0.1 and 0.25 μg/mL target protein are too 
low to yield a reliable signal, whereas 0.5 μg/mL or 1 μg/mL of target protein 
would be optimal if the lysate protein concentration was 0.1 mg/mL. FKBP12 
binding to Rapamycin is inhibited when the lysate protein is at 1 mg/mL.
C. Screening—It is common for most HTS formats to first execute a small pilot screen. 
The purpose of the pilot screen is to validate or optimize the protein target/lysate 
concentrations mentioned above, aiming to minimize background noise and maximize 
positive signals. This part of the screening process will use four identical slides to test two 
different target protein concentrations in the lysate preparation. After the image analysis is 
performed, the hit rates in the two conditions are compared and the concentration with the 
optimal hit rate (<1%) will be used in the SMM screen. The pilot screen is performed as 
follows:
21 Prepare the following solutions: Solution 1 (6 mL of 0.5 μg/mL target protein 
expressed in lysate containing 0.3 mg/mL total protein) and Solution 2 (6 mL of 
1 μg/mL target protein expressed in lysate containing 0.3 mg/mL concentration). 
Using concentration values obtained in step 12 of Support Protocol, dilute 
stock lysate in MIPP buffer such that the target concentration is ~0.5 μg/ml. 
Knowing the total protein concentration of stock lysate, calculate the total 
protein concentration after the above dilution. If it is < 0.3 mg/ml adjust diluted 
lysate concentration to 0.3 mg/ml using the mock HEK293 lysate.
22 Incubate, wash and read-out two slides in Solution 1 and two slides in Solution 2 
following instructions presented in the Assay development procedure (section 
A, steps 3–14)
23 Perform the data analysis procedure described in the Screening and Data 
analysis (Section D, steps 24–28) and choose the ideal target protein/lysate 
concentration to be used in the SMM screen. The ideal concentration setup is the 
one that produces the best signal to noise ratio for a given control.
D. Screening and Data Analysis
24 Prepare sufficient SMM ready lysate (as determined in the pilot screen 
protocol), and incubate each SMM slide with 3 mL lysate solution according to 
the procedure described in the Assay development (Section A, steps 3–14).
25 Perform image analysis following the steps outlined in the Assay development 
data analysis (Section B, steps 1–6).
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26 Nearly all of the remaining data analysis steps can be carried out using simple 
statistical software such as EasyFit and simple operations are described in user-
friendly guides that come with this software. First, generate F/B distributions for 
every block of each slide screened (please refer to slide layout from previous 
protocol (Clemons et al., 2010).
27 Fit the generated distributions to a Cauchy distribution model (Johnson et al., 
1994) with F/B ratios <0.7 and >1.3 being excluded from the fitting. A Cauchy 
distribution model, which is a continuous probability distribution, is 
characterized by its amplitude rather than its mean and variance, which are 
undefined. The major characteristic of a Cauchy distribution is a “heavy tail”. 
Statistical software packages such as EasyFit can be used to fit the F/B 
distributions into a Cauchy model.
28 After the model is fit on all the blocks, assign P-values for all data points 
including the ones that were excluded. This step can also be done using the 
software program EasyFit. Compounds that show a P-value of 7% or less with 
an F/B ratio >1 in all four replicates are typically assigned as assay positives.
Note: The number of unique assay positives divided by the total number of unique 
compounds screened constitutes the hit ratio, which is determined during the pilot screen. 
The ideal hit rate should under 1%. In the example illustrated in figure 3, both 
concentrations yielded an acceptable hit rate. The 0.5 μg/mL condition resulted in more hits 
than the 1 μg/mL condition, thus the 0.5 μg/mL concentration was used in the SMM screen.
Reagents and solutions
Expression plasmid encoding the HA-tagged target protein
Transfection reagent: Use a highly efficient low toxicity reagent
Infectious lentiviral particles encoding the HA-tagged target protein
MIPP lysis buffer (use Milli-Q water or equivalent)




0.5% [v/v] Triton X-100





50 mM Tris [pH 7.6]
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0.5% BSA (to antibody incubations)
COMMENTARY
Background information
Small-molecule microarray screening is a high-throughput binding assay involving the 
fluorescence-based detection of protein-small molecule interactions where protein targets 
bind molecules arrayed on glass slides. The protein target used in the screening process can 
be in either purified format or from cell lysate. Lysates have advantages for use with SMM. 
Many protein targets are difficult to purify or unstable in standard buffer systems. Moreover, 
the presence of soluble cellular proteins in the lysates significantly reduces the background 
noise. The signal intensity is expressed as a function of signal-to-noise ratio (SNR). The 
final list of putative assay positives consists of compounds that score above a stringent 
arbitrary SNR cut-off and are reproducible in all replicates.
Critical parameters
Choice of cellular context for target expression and target/lysate 
concentration—In our experience, target expression in HEK293T results in functional 
protein for most targets. For some targets, it may be more relevant for the target to be 
expressed in a specific cell type or cells subjected to a specific condition (e.g. heat shock, or 
treatment with a small-molecule inhibitor). In such cases, additional optimization steps may 
be required to determine optimal levels of cell number, plasmid DNA for transient 
transfection, or lentiviral particles. It is also important to monitor the amount of expressed 
target and the total protein concentration. For example, high total protein may decrease 
specific signal intensities, whereas low total protein may result in an increase in false-
positive hits.
Tag and antibody selection—It is possible to use other epitope tags such as the Flag, 
His, SBP, and myc tags. However, it is essential that the anti-tag antibody is highly specific. 
In this protocol the HA tag was selected due to the high specificity of the HA antibody.
Incubation steps—It is important to minimize room temperature exposure during lysate 
and antibody incubation so as to avoid denaturation.
Troubleshooting
No signals above background noise—Hit rates in SMM screens can vary 
significantly and largely depend on the nature of the compound collection printed on the 
array as well as the nature of the protein target. In the case where no assay positives are 
observed during the pilot screen a few steps and reagents should be verified and/or adjusted. 
For example, check that the scanning parameters are sufficiently sensitive for low signals. In 
addition, the amount of protein target may be increased.
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Excessively high hit rate—A great concern is a hit rate greater than 1%. This usually 
points to a potential surface chemistry problem often involving excessive surface activation 
or loading levels that results in high nonspecific binding. This issue needs to be addressed 
by the chemist charged with SMM manufacture.
Anticipated results
Based on our previous experience with various targets screened in lysate format, particularly 
in the case of transcription factors, it is expected that each screen will achieve hit rates in the 
range 0.1% to 1%. For example, a recent screen that resulted in a published probe for the 
ETV1 oncogenic transcription factor yielded an average hit rate of about 0.5% (Pop et al., 
2014). Approximately 70–80% of SMM hits confirm binding in a secondary biophysical 
assay (e.g. thermal shift, SPR, ITC). Since SMM is a pure binding assay that does not 
involve interrogating biological functions, it is expected that the number of putative hits that 
bind and perturb a biological activity is significantly lower, especially for targets lacking 
known enzymatic activities that are easily followed in biochemical assays. Nevertheless, 
SMMs have successfully enabled the discovery of novel inhibitors (Hong et al., 2014).
Time considerations
The optimization of target expression in a particular cell line may take up to a week until the 
final optimal values are identified. A pilot screen, if necessary, will require an additional 3–4 
days to establish the screening parameters. Once all conditions are known and all reagents 
are in hand, the screen itself can be performed in one day including the image acquisition. If 
the compound collection is large (>100,000) an additional day or two may be needed for 
image acquisition alone. Data analysis will require several days. In total, a target can be 
screened in 3 to 4 weeks when accounting for assay development, screening, and data 
analysis.
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Figure 1. Schematic diagram of a representative printed SMM
This particular array layout involves 12,288 features arrayed in 48 16×16 subarrays. Printed 
features are typically 150 μm in diameter for this array density. Each subarray contains 256 
features and is created by a single pin from the 48-pin printhead. The subarrays are laid out 
in the same 4×12 configuration as the printhead. For subarray 37, the pin would pick up 
samples from wells D01, D13, H01, H13, L01, L13, P01, and P13 of each plates loaded onto 
the arrayer if printed in sequence. In this configuration, 32 features of each subarray are 
dedicated to printed dye sentinels for grid alignment (see section on Data Analysis). This 
configuration also features 20 DMSO vehicle controls and 8 known ligand positive controls 
per subarray. Positive and negative controls can enable QC analysis of the manufacture and 
screening processes as well assist in data analysis methods. Barcodes are particularly useful 
when tracking slide and the barcodes usually correspond to saved .tiff image files for 
screened slides and .gpr files corresponding to raw data analysis (see section on Screening 
and Data Analysis).
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Figure 2. FKBP12 binding to Rapamycin as a representative protein-small molecule interaction 
on an SMM
Varying concentrations of pure FKBP12 were diluted in TBST (blue) or 293T lysates 
(green) and subjected to small molecule microarray screen using arrays containing 
Rapamycin. Image analysis demonstrates that the signal intensity is significantly affected by 
the amount of FKBP12 protein screened. The y-axis represents the F/B ratios and the x-axis 
shows the FKBP12 protein concentrations in buffer or lysate, as indicated.
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Figure 3. Example of a pilot screen result
(a) The percent hit rate for each target protein concentration. (b) Venn diagram overlap for 
the hits identified in the pilot screen. 24 hits were common between the two conditions, 26 
hits were unique to the 0.5 μg/mL concentration and 11 hits were unique to the 1 μg/mL 
concentration.
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